An integrated analysis of the association between Ts gene polymorphisms and clinical outcome in gastric and colorectal cancer patients treated with 5-FU-based regimens

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Molecular Biology Reports

• Publication date

  2013-05-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11033-013-2557-8PMID 23645036
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer.

  2011cited by this paper
• Combinations of Polymorphisms in Genes Involved in the 5-Fluorouracil Metabolism Pathway Are Associated with Gastrointestinal Toxicity in Chemotherapy-Treated Colorectal Cancer Patients

  2011cited by this paper
• Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil.

  2011cited by this paper
• TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients

  2011cited by this paper
• Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study.

  2011cited by this paper
• Influence of thymidylate synthase DNA polymorphisms and gender on the clinical evolution of patients with advanced colorectal cancer.

  2010cited by this paper
• Variants in the Dihydropyrimidine Dehydrogenase, Methylenetetrahydrofolate Reductase and Thymidylate Synthase Genes Predict Early Toxicity of 5-Fluorouracil in Colorectal Cancer Patients

  2010cited by this paper
• Relationship of polymorphism of the tandem repeat sequence in the thymidylate synthase gene and the survival of stage III colorectal cancer patients receiving adjuvant 5‐flurouracil‐based chemotherapy

  2010cited by this paper
• TS Gene Polymorphisms Are Not Good Markers of Response to 5-FU Therapy in Stage III Colon Cancer Patients

  2010cited by this paper
• Polymorphism of thymidylate synthase gene and chemosensitivity of 5‐fluorouracil regimen in metastatic gastrointestinal cancer

  2009cited by this paper
• Comparative analysis of thymidylate synthase at the protein, mRNA, and DNA levels as prognostic markers in colorectal adenocarcinoma

  2009cited by this paper
• Correlation Between Thymidylate Synthase Protein Expression and Gene Polymorphism with Clinicopathological Parameters in Colorectal Carcinoma

  2009cited by this paper
• Combination of polymorphisms within 5' and 3' untranslated regions of thymidylate synthase gene modulates survival in 5 fluorouracil-treated colorectal cancer patients.

  2009cited by this paper
• Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer

  2009cited by this paper
• Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer

  2008cited by this paper
• Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer

  2008cited by this paper
• Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphisms and Toxicity to Capecitabine in Advanced Colorectal Cancer Patients

  2008cited by this paper
• Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy

  2008cited by this paper
• Discerning the Ancestry of European Americans in Genetic Association Studies

  2007influential reference
• Practical methods for incorporating summary time-to-event data into meta-analysis

  2007cited by this paper
• Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma?

  2007cited by this paper
• Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.

  2006cited by this paper
• Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil.

  2006cited by this paper
• Genotype of thymidylate synthase likely to affect efficacy of adjuvant 5-FU based chemotherapy in colon cancer.

  2006cited by this paper
• Orotate Phosphoribosyltransferase Gene Polymorphism Predicts Toxicity in Patients Treated with Bolus 5-Fluorouracil Regimen

  2006cited by this paper
• Studying the predictive/prognostic role of thymidylate synthase genotypes in patients with colorectal cancer: Is one polymorphism enough?

  2005cited by this paper
• Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers.

  2005cited by this paper
• Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity.

  2005cited by this paper
• Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil

  2005cited by this paper
• Loss of Heterozygosity at the Thymidylate Synthase (TS) Locus on Chromosome 18 Affects Tumor Response and Survival in Individuals Heterozygous for a 28-bp Polymorphism in the TS Gene

  2004cited by this paper
• Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma.

  2004cited by this paper
• Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis.

  2004cited by this paper
• Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer.

  2003cited by this paper
• Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene.

  2003cited by this paper
• 5-Fluorouracil: mechanisms of action and clinical strategies

  2003cited by this paper
• Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer

  2002cited by this paper
• Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer.

  2001cited by this paper
• A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil

  2001cited by this paper
• Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy

  2001cited by this paper
• Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114.

  1997cited by this paper
• The incorporation of 5-fluoro-2'-deoxyuridine into DNA of mammalian tumor cells.

  1981cited by this paper
• 5-Fluoro-2'-deoxyuridine incorporation in L1210 DNA.

  1981cited by this paper
• Structures of reversible and irreversible complexes of thymidylate synthetase and fluorinated pyrimidine nucleotides.

  1974cited by this paper
• Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory Compounds

  1957cited by this paper

• Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects

  2023cites this paper
• Predicting drug response and toxicity in metastatic colorectal cancer: the role of germline markers

  2022cites this paper
• 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition.

  2021cites this paper
• Customized Chemotherapy in Advanced Gastric Cancer

  2017cites this paper
• association of thymidylate synthase expression and clinical outcomes of gastric cancer patients treated with fluoropyrimidine-based chemotherapy: a meta-analysis

  2016cites this paper
• Thymidylate Synthase Polymorphisms and Risk of Lung Cancer among the Jordanian Population: a Case Control Study.

  2016cites this paper
• Association of thymidylate synthase expression and clinical outcomes of gastric cancer patients treated with fluoropyrimidine-based chemotherapy: a meta-analysis

  2016cites this paper
• association of thymidylate synthase expression and clinical outcomes of gastric cancer patients treated with fluoropyrimidine-based chemotherapy: a meta-analysis

  2016cites this paper
• Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker?

  2016cites this paper
• Prognostic implications of thymidylate synthase gene polymorphisms in patients with advanced small bowel adenocarcinoma treated with first-line fluoropyrimidine-based chemotherapy.

  2015cites this paper
• Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.

  2015cites this paper
• X‐ray repair cross‐complementing 1 polymorphism and prognosis of platinum‐based chemotherapy in gastric and colorectal cancer: A meta‐analysis

  2014cites this paper
• A Functional Germline Variant in GLI1 Implicates Hedgehog Signaling in Clinical Outcome of Stage II and III Colon Carcinoma Patients

  2014cites this paper
• Thymidine phosphorylase gene variant, platelet counts and survival in gastrointestinal cancer patients treated by fluoropyrimidines

  2014cites this paper
• Are the loan loss and fair value components of bank income rationally priced

  2013cites this paper